|
| |
Hollis-Eden PharmaceuticalsHollis-Eden Pharmaceuticals is a development-stage pharmaceutical company, is engaged in the discovery, development and commercialization of products for the treatment of a number of targeted disease states caused byviral, bacterial, parasitic or fungal infections, including HIV/AIDS, hepatitis B and C, and malaria. The Company has three technology platforms, one based on cellular energy regulation, the second on a unique immune system modulation technology, and the third on biochemical synthesis regulators. The Company believes that certain of its drug candidates may provide the first long-term treatment for HIV without the development of viral strain resistance to the drugs' effectiveness, significant toxicity or severe side effects.
| Contact Details: |
| 4435 Eastgate Mall Suite, 400 |
| San Diego |
| CA |
| 92121 |
| United States of America |
| Tel: | (858)587-9333 |
| Fax: | (858)558-6470 |
| Email: | Info@holliseden.com |
| WWW: | www.holliseden.com/
|
|
Loading...
|
Recent Publications by Hollis-Eden Pharmaceuticals: |  |
HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease.
HE3286 (17alpha-ethynyl-5-androstene-3beta, 7beta, 17beta-triol) is a... | 30th October, 2009
| Hollis-Eden Pharmaceuticals, San Diego, California 92121, USA.
| Ann N Y Acad Sci. 2009 Sep;1173:781-90.
DOI Direct Link |
Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235).
Androst-5-ene-3beta, 17beta-diol (AED) is an adrenal hormone that has been... | 25th April, 2009
| Hollis-Eden Pharmaceuticals, San Diego, CA 92121, USA.
| Br J Cancer. 2009 Apr 7;100(7):1068-72.
DOI Direct Link |
A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cells.
Dehydroepiandrosterone (DHEA) has attracted much interest because of its... | 13th December, 2007
| Hollis-Eden Pharmaceuticals, San Diego, California, USA.
| Ann N Y Acad Sci. 2007 Sep;1110:630-40.
DOI Direct Link |
Safety and activity of the immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients.
Twenty-five AIDS patients were treated with HE2000, a synthetic adrenal... | 31st October, 2007
| Hollis-Eden Pharmaceuticals, Inc., 4435 Eastgate Mall, Suite 400, San
| Antimicrob Agents Chemother. 2007 Jul;51(7):2639-41. Epub 2007 Apr 30.
DOI Direct Link |
5-androstenediol improves survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression.
We previously reported that five daily intramuscular doses of... | 5th June, 2007
| Hollis-Eden Pharmaceuticals Inc, San Diego, CA 92121, USA.
| Int Immunopharmacol. 2007 Apr;7(4):500-5. Epub 2007 Jan 12.
DOI Direct Link |
→View more Hollis-Eden Pharmaceuticals research publications. |
Press Releases on Hollis-Eden Pharmaceuticals:
|
 |
| Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference |
16th November, 2009 |
Hollis-Eden Pharmaceuticals, Inc. |
BOSTON, Nov. 16 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for
|
| Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference |
12th November, 2009 |
Hollis-Eden Pharmaceuticals, Inc. |
SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), will present results of its ongoing human clinical Phase I/II open-label dose-ranging trial with Apoptone
|
| Hollis-Eden Pharmaceuticals Retains Burrill LLC to Provide Exclusive Advisory Services for Lead Programs |
20th October, 2009 |
Hollis-Eden Pharmaceuticals |
SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals (Nasdaq: HEPH) has retained Burrill LLC to provide exclusive strategic advisory services, with an initial focus on partnering
|
| Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO |
15th June, 2009 |
Hollis-Eden Pharmaceuticals, Inc. |
SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), a leader in the development of a new class of small molecule compounds based on endogenous adrenal
|
| New Report from PharmaPlus: HIV Pipelines & Deals |
1st December, 2003 |
Pharmaplus |
New Report from PharmaPlus: HIV Pipelines & Deals
At the end
of November 2003 the joint United Nations Program on HIV/AIDS and the World
Health Organization presented
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 382 times since April 2007, the link to the organisation's website has been followed 74 times Recent Search Terms used to find this page: hollis eden | . Search for more companies in San Diego Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Hollis-Eden Pharmaceuticals |
